AstraZeneca wins FDA approval for key new lung cancer pill

LONDON, Nov 13 (Reuters) - A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, was approved by U.S. regulators on Friday, in a boost for the British drugmaker.